Sumatriptan / naproxen

A combination of sumatriptan (a triptan) and naproxen (an NSAID), FDA-approved for acute migraine with or without aura, ages 12 and older.

psilodex.org/m/sumatriptan-naproxen · data v2026.10.04

Clinical contraindication: None listed; No clinical contraindication identified.
Psilocybin evidence: Mechanism only
Half-life: ~2 h; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Sumatriptan / naproxen”, v2026.10.04. psilodex.org/m/sumatriptan-naproxen

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

Availability

Sources [1]

FDA-approved for

Acute treatment of migraine with or without aura (adults and children 12 and older)

Sources [1]

Other safety

Boxed warning: the NSAID component (naproxen) increases the risk of serious cardiovascular thrombotic events, including heart attack and stroke, and of serious gastrointestinal bleeding, ulceration and perforation, which can be fatal.

About the medication itself, separate from any interaction with psilocybin.

Sources [1]

01 Interaction with psilocybin

In theory it may add to psilocybin's serotonin activity and blood pressure rise; the label reports rare significant blood pressure elevation.

Detail In theory, sumatriptan's serotonin activity and both components' blood pressure effects may add to psilocybin's serotonergic effects and transient blood pressure rise; no data. The label reports rare significant blood pressure elevation, serotonin syndrome with other serotonergic drugs, and seizures.

Human data with psilocybin: None known: no published human data with psilocybin
Half-life: Sumatriptan ~2 h; naproxen ~19 h (FDA label, checked 2026-10-03)

Evidence types on this record

Mechanism onlyMechanism only (theoretical)

02 Pharmacology relevant to psilocybin

3 listed · counted on reports

Raises blood pressure or heart rate: Raises blood pressure or heart rate. Psilocybin raises both for several hours, so the effects can add. Sources [1]
Lowers seizure threshold or carries seizure risk: Makes a seizure more likely, or has been linked to seizures. Sources [1]
Serotonergic: Increases serotonin activity, for example by blocking its reuptake or releasing it. Psilocybin acts on serotonin receptors, so effects can add together. With antidepressant use, the psilocybin response can be weaker. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-02

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

TREXIMET (sumatriptan and naproxen sodium) tablets (Currax) · FDA label (DailyMed) — revised 2024-12-23 | raises_bp_hr: "Significant elevation in blood pressure, including hypertensive crisis with acute impairment of organ systems, has been reported on rare occasions in patients treated with 5-HT 1 agonists, including sumatriptan, a component of TREXIMET." | serotonergic: "Serotonin syndrome may occur with TREXIMET, particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs)" | seizure_threshold: "Seizures have been reported following administration of sumatriptan." | half_life: "The elimination half-life of sumatriptan is approximately 2 hours." | about: "The plasma half-life of the naproxen anion in humans is approximately 19 hours"

Record history

v2026.10.02First published.
2026-10-03Last reviewed against its sources.

Report an error in this record →